Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
Warning: file_get_contents(http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=9409197&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 445
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Isoprostanes: potential markers of oxidant stress in atherothrombotic disease Patrono C; FitzGerald GAArterioscler Thromb Vasc Biol 1997[Nov]; 17 (11): 2309-15Isoprostanes are emerging as a new class of biologically active products of arachidonic acid metabolism of potential relevance to human vascular disease. Their formation in vivo seems to reflect primarily, if not exclusively, a nonenzymatic process of lipid peroxidation. Enhanced urinary excretion of 8-iso-PGF2 alpha has been described in association with cardiac reperfusion injury and with cardiovascular risk factors, including cigarette smoking, diabetes mellitus, and hypercholesterolemia. Besides providing a likely noninvasive index of lipid peroxidation in these settings, measurements of specific F2 isoprostanes in urine may provide a sensitive biochemical end point for dose-finding studies of natural and synthetic inhibitors of lipid peroxidation. Although the biological effects of 8-iso-PGF2 alpha in vitro suggest that it and other isoeicosanoids may modulate the functional consequences of lipid peroxidation, evidence that this is likely in vivo remains inadequate at this time.|*Lipid Peroxidation[MESH]|*Oxidative Stress[MESH]|Antioxidants/pharmacology[MESH]|Arteriosclerosis/*metabolism[MESH]|Biomarkers[MESH]|Cardiovascular Diseases/epidemiology/metabolism[MESH]|Diabetes Mellitus/metabolism[MESH]|Dinoprost/analogs & derivatives/pharmacology/urine[MESH]|F2-Isoprostanes[MESH]|Free Radicals[MESH]|Gas Chromatography-Mass Spectrometry[MESH]|Humans[MESH]|Hyperlipidemias/metabolism[MESH]|Immunoassay[MESH]|Indicator Dilution Techniques[MESH]|Platelet Aggregation/drug effects[MESH]|Prostaglandins F/*analysis[MESH]|Risk Factors[MESH]|Thrombosis/*metabolism[MESH]|Vasoconstrictor Agents/pharmacology[MESH] |
